Neequaye J, Viza D, Pizza G, Levine P H, De Vinci C, Ablashi D V, Biggar R J, Nkrumah F K
University of Ghana School of Medicine, Accra.
Anticancer Res. 1990 Sep-Oct;10(5A):1183-7.
Twenty-seven children with abdominal Burkitt's lymphoma (stage III), who had achieved complete remission, were entered into a prospective controlled trial of adjunct treatment with Epstein-Barr virus (EBV)-specific transfer factor (TF). Two patients treated with TF and 2 controls relapsed early (less than or equal to 12 weeks). Two out of 12 TF-treated patients and 5 out of 11 controls subsequently suffered relapses. Time to first late relapse was longer among TF-treated patients (p = 0.08), and no late relapse occurred while a patient was receiving TF treatment. Thus it seems that specific TF might be useful in the management of endemic Burkitt's lymphoma and also in the treatment of other virus-associated cancers and diseases.
27例腹部伯基特淋巴瘤（Ⅲ期）且已完全缓解的儿童进入了一项关于使用爱泼斯坦-巴尔病毒（EBV）特异性转移因子（TF）进行辅助治疗的前瞻性对照试验。2例接受TF治疗的患者和2例对照者早期复发（小于或等于12周）。12例接受TF治疗的患者中有2例以及11例对照者中有5例随后复发。TF治疗组患者首次晚期复发的时间更长（p = 0.08），且在患者接受TF治疗期间未发生晚期复发。因此，特异性TF似乎可用于地方性伯基特淋巴瘤的管理，也可用于治疗其他病毒相关的癌症和疾病。
